4.135
price up icon3.10%   0.135
 
loading
Cabaletta Bio Inc stock is traded at $4.135, with a volume of 217.97K. It is up +3.10% in the last 24 hours and down -3.19% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$4.00
Open:
$3.99
24h Volume:
217.97K
Relative Volume:
0.21
Market Cap:
$198.57M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-2.3902
EPS:
-1.73
Net Cash Flow:
$-54.24M
1W Performance:
-1.81%
1M Performance:
-3.19%
6M Performance:
-66.72%
1Y Performance:
-74.23%
1-Day Range:
Value
$3.965
$4.165
1-Week Range:
Value
$3.49
$4.25
52-Week Range:
Value
$3.4713
$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Name
Cabaletta Bio Inc
Name
Phone
(267) 759-3100
Name
Address
2929 ARCH STREET, PHILADELPHIA, PA
Name
Employee
138
Name
Twitter
@CabalettaBio
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CABA's Discussions on Twitter

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-05-23 Initiated Citigroup Buy
Jul-18-23 Initiated Guggenheim Buy
Jan-27-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-30-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-08-21 Initiated Wells Fargo Overweight
Oct-19-21 Resumed Morgan Stanley Overweight
Jun-30-21 Initiated Mizuho Buy
Jan-08-21 Initiated Chardan Capital Markets Buy
Oct-13-20 Initiated H.C. Wainwright Buy
Nov-19-19 Initiated Cowen Outperform
Nov-19-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Morgan Stanley Overweight
View All

Cabaletta Bio Inc Stock (CABA) Latest News

pulisher
02:11 AM

Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com

02:11 AM
pulisher
Nov 04, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN

Nov 03, 2024
pulisher
Oct 30, 2024

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance

Oct 30, 2024
pulisher
Oct 28, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha

Oct 25, 2024
pulisher
Oct 22, 2024

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha

Oct 22, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com

Oct 17, 2024
pulisher
Oct 14, 2024

Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha

Oct 10, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa

Oct 10, 2024
pulisher
Oct 10, 2024

Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily

Oct 09, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks

Oct 07, 2024
pulisher
Oct 04, 2024

Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Oct 04, 2024
pulisher
Oct 02, 2024

Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio secures lease terms through August 2026 - Investing.com India

Oct 01, 2024
pulisher
Sep 30, 2024

Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 30, 2024
pulisher
Sep 28, 2024

Lynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Cabaletta Bio stock pioneers CAR-T in immunology amid challenges - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Lynx1 Capital Management LP Has $3.68 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 27, 2024
pulisher
Sep 27, 2024

Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN

Sep 27, 2024
pulisher
Sep 26, 2024

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - ForexTV.com

Sep 26, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Reduces Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR - EIN News

Sep 25, 2024
pulisher
Sep 25, 2024

Cabaletta Bio Inc (CABA) Performance and Fundamentals Dashboard tells a completely different story - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Cabaletta Bio Inc Inc. (CABA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Sep 25, 2024
pulisher
Sep 25, 2024

Balance Sheet Breakdown: Cabaletta Bio Inc (CABA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Sep 25, 2024
pulisher
Sep 23, 2024

Technical analysis of Cabaletta Bio Inc (CABA) stock chart patterns - US Post News

Sep 23, 2024
pulisher
Sep 18, 2024

Nothing is Better Than Cabaletta Bio Inc (CABA) stock at the moment - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Cabaletta Bio Inc: Navigating Market Fluctuations with a 204.68M Market Cap - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Purchased by E Fund Management Co. Ltd. - MarketBeat

Sep 18, 2024
pulisher
Sep 17, 2024

Cabaletta Bio shares maintain Buy rating from H.C. Wainwright - Investing.com India

Sep 17, 2024
pulisher
Sep 17, 2024

Cabaletta Bio (NASDAQ:CABA) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Cabaletta Bio shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com UK

Sep 17, 2024
pulisher
Sep 16, 2024

Financial Fitness Check: Examining Cabaletta Bio Inc (CABA)’s Key Ratios - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

Was anything positive for Cabaletta Bio Inc (CABA) stock last session? - US Post News

Sep 16, 2024
pulisher
Sep 15, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Sep 15, 2024
pulisher
Sep 15, 2024

TD Asset Management Inc Raises Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Sep 15, 2024

Cabaletta Bio Inc Stock (CABA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cabaletta Bio Inc Stock (CABA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Binder Gwendolyn
See Remarks
Jan 19 '24
Sale
19.59
11,000
215,439
20,000
Binder Gwendolyn
See Remarks
Dec 19 '23
Option Exercise
1.01
11,000
11,110
31,000
Binder Gwendolyn
See Remarks
Dec 19 '23
Sale
21.89
11,000
240,789
20,000
Binder Gwendolyn
See Remarks
Nov 20 '23
Option Exercise
1.01
11,000
11,110
31,000
Binder Gwendolyn
See Remarks
Nov 20 '23
Sale
17.82
11,000
196,014
20,000
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):